Stay updated on Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial
Sign up to get notified when there's something new on the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page.

Latest updates to the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page
- Check5 days agoChange DetectedThe study’s Publications section now lists a newer/updated bibliographic version of the JAMA Dermatology LIBERTY-CSU CUPID phase 3 trial citation (with the final April issue details instead of the earlier online-ahead-of-print entry). The page header footer revision identifier was also updated (v3.5.3), reflecting a site update rather than study content.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check42 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check49 days agoChange DetectedRevision: v3.4.3 was added to the page, replacing the previous Revision: v3.4.2.SummaryDifference0.0%

- Check56 days agoChange DetectedA new publication citation is added to the Publications section: Gimenez-Arnau AM et al. Dupilumab Improves Health-Related Quality of Life in Omalizumab-Naive Patients with Chronic Spontaneous Urticaria. Dermatol Ther (Heidelb). 2026 Jan;16(1):549-562 (doi:10.1007/s13555-025-01605-w; Epub 2025 Dec 2). The prior 2025 Dec 2 'Online ahead of print' entry is removed.SummaryDifference0.0%

- Check63 days agoChange DetectedAdded a new publication reference: Casale TB, Saini SS, Ben-Shoshan M, Gimenez-Arnau AM, Bernstein JA, Hayama K, Amin N, Robinson LB, Bauer D, Dakin P, Laws E, Radin A, Makhija M. Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials. JAMA Dermatol. 2026 Feb 18:e256023.SummaryDifference0.0%

- Check78 days agoChange DetectedAddition of Revision: v3.4.2 is shown on the page. The funding/status notices have been removed (including the lapse in government funding message and the earlier Revision: v3.4.1 reference).SummaryDifference0.2%

Stay in the know with updates to Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page.